Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)

CAR-T Digest - August 2020

Weekly Digest - September 2024

24 Sep 2024: Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)

Araris Biotech has entered into an agreement to acquire Innate Pharma’s portfolio of patents related to ADC transglutaminase conjugation technology
This acquisition positions Araris as a leader in developing ADCs that utilize transglutaminase conjugation technology, enhancing its capabilities in the field
The acquired patents cover a wide range of uses for bacterial transglutaminase in the conjugation of various linker-payloads to antibodies, broadening Araris’s development opportunities for next-generation site-specific ADCs

For full story click here